CTLA4 and isolated hemihyperplasia: In total, 98% of patients with CTLA-4 inhibitor-related IH had pituitary enlargement [38], while only 28% of patients with PD-1/PD-L1 inhibitor-related IH developed pituitary enlargement [38].